Adagio Medical Holdings (ADGM) Cash & Equivalents (2023 - 2026)

Adagio Medical Holdings has disclosed Cash & Equivalents across 4 years of filings, most recently posting $7.7 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 5.61% year-over-year to $7.7 million; the TTM figure through Jun 2026 stood at $7.7 million (down 5.61% YoY), while the FY2025 annual figure was $17.1 million, down 16.97% from the prior year.
• Cash & Equivalents came in at $7.7 million for Q2 2026 at Adagio Medical Holdings, down from $12.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $28.3 million in Q3 2024 to a low of $1.4 million in Q4 2023.
• Average Cash & Equivalents over 4 years is $12.7 million, with a median of $12.9 million recorded in 2026.
• Year-over-year, Cash & Equivalents surged 1389.52% in 2024 and tumbled 83.39% in 2025.
• Over 4 years, Cash & Equivalents stood at $1.4 million in 2023, then surged by 1389.52% to $20.6 million in 2024, then fell by 16.97% to $17.1 million in 2025, then plunged by 54.75% to $7.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $7.7 million in Q2 2026, $12.9 million in Q1 2026, and $17.1 million in Q4 2025.